Jasper Therapeutics (JSPR) said Wednesday that preliminary data from an ongoing phase 1b/2a study of subcutaneously administered briquilimab as a treatment for chronic spontaneous urticaria showed "substantial reductions" in disease activity.
The company said the 49-patient study showed clinical responses as early as one week after the first dose as well as "durable" clinical responses across multiple doses.
Chronic spontaneous urticaria is a condition which causes hives to appear.
Jasper Therapeutics' shares were down 44% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。